New Alzheimer's drug: only a few eligible for treatment
It is estimated that less than one in ten people with dementia are eligible for treatment with Lecanemab or Leqembi, the slowing agent that is still allowed on the European market by the European Medicines Agency (EMA). Nevertheless, the director of …